Shandong Keyuan Pharmaceutical Co., Ltd. (SHE:301281)
China flag China · Delayed Price · Currency is CNY
34.27
-1.48 (-4.14%)
Nov 17, 2026, 4:00 PM EST

SHE:301281 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
575.03395.19457.46445.94442.31419.67
Other Revenue
3.043.046.261.640.551.22
578.07398.23463.72447.58442.87420.89
Revenue Growth
32.73%-14.12%3.60%1.06%5.22%14.67%
Cost of Revenue
273.06201.9266.76240.86264.82246.14
Gross Profit
305.01196.33196.96206.73178.04174.75
Selling, General & Admin
180.98131.53116.1299.7256.0363.1
Research & Development
25.8942.3535.8243.8626.9724.43
Other Operating Expenses
5.682.554.194.365.34.47
Operating Expenses
218.92178.21156.42148.2589.1492.11
Operating Income
86.0918.1240.5458.4888.9182.64
Interest Expense
-1.11-0.02-0.04---
Interest & Investment Income
3.537.0215.415.971.330.96
Currency Exchange Gain (Loss)
0.040.04-0.591.151.55-1.11
Other Non Operating Income (Expenses)
1.080.07-2.030.09-0.320.05
EBT Excluding Unusual Items
89.6325.2453.2975.791.4782.55
Impairment of Goodwill
-0.8-0.8----
Gain (Loss) on Sale of Investments
-1.02-1.160.80.54--
Gain (Loss) on Sale of Assets
-0.42-0.26-0.840.040.37-0.04
Asset Writedown
1.21-----
Legal Settlements
-16.11-16.11-0.14---
Other Unusual Items
9.879.8712.613.456.477.41
Pretax Income
82.3616.7865.7179.7498.389.92
Income Tax Expense
10.410.45.442.77.0211.75
Earnings From Continuing Operations
71.9516.3860.2777.0491.2878.17
Minority Interest in Earnings
-1.530.180.18---
Net Income
70.4316.5560.4577.0491.2878.17
Net Income to Common
70.4316.5560.4577.0491.2878.17
Net Income Growth
34.82%-72.62%-21.54%-15.60%16.77%13.87%
Shares Outstanding (Basic)
1101101081018181
Shares Outstanding (Diluted)
1101101081018181
Shares Change
2.21%2.23%6.49%24.38%0.53%-0.47%
EPS (Basic)
0.640.150.560.761.120.96
EPS (Diluted)
0.640.150.560.761.120.96
EPS Growth
31.90%-73.21%-26.32%-32.14%16.15%14.40%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-16.34-93.58-356.9-33.1284.7531.83
Free Cash Flow Per Share
-0.15-0.85-3.31-0.331.040.39
Dividend Per Share
0.0500.0500.2000.3000.286-
Dividend Growth
-75.00%-75.00%-33.33%5.00%--
Gross Margin
52.76%49.30%42.47%46.19%40.20%41.52%
Operating Margin
14.89%4.55%8.74%13.06%20.08%19.63%
Profit Margin
12.18%4.16%13.04%17.21%20.61%18.57%
Free Cash Flow Margin
-2.83%-23.50%-76.96%-7.40%19.14%7.56%
EBITDA
134.3665.7887.4107.43122.54109.5
EBITDA Margin
23.24%16.52%18.85%24.00%27.67%26.02%
D&A For EBITDA
48.2747.6746.8648.9533.6326.86
EBIT
86.0918.1240.5458.4888.9182.64
EBIT Margin
14.89%4.55%8.74%13.06%20.08%19.63%
Effective Tax Rate
12.64%2.39%8.27%3.38%7.14%13.06%
Revenue as Reported
578.07398.23463.72447.58442.87420.89
Advertising Expenses
-4.094.031.89--